Possible benefits of reformulating antiviral drugs with nanoemulsion system in the treatment of novel coronavirus infection

Coronaviruses ◽  
2020 ◽  
Vol 01 ◽  
Author(s):  
Manish Kumar ◽  
Chandra Prakash Jain
Keyword(s):  
Drug Delivery ◽  
Drug Therapy ◽  
Pulmonary Surfactant ◽  
Antiviral Drug ◽  
Treatment Strategies ◽  
Drug Dosage ◽  
Antiviral Drugs ◽  
Antiviral Action ◽  
Coronavirus Infection ◽  
Novel Coronavirus

Background: An outbreak of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection or COVID 19, causing serious threats to all around the world. Until an effective and safe vaccine for novel coronavirus is developed by scientists, current drug therapy should by optimize for the control and treatment of COVID 19. Objective: In this manuscript, we are presenting a perspective on possible benefits of reformulating antiviral drug dosage form with nanoemulsion system against novel coronavirus infection. Methods: Literature review has been done on COVID 19, treatment strategies, novel drug delivery systems and role of pulmonary surfactant on lungs protection. Results: Nanoemulsion system and its components have certain biophysical properties which could increase the efficacy of drug therapy. Antiviral drugs, delivered through a nanoemulsion system containing P-gp inhibitor (surfactant and cosolvent), can inhibit the cellular resistance to drugs and would potentiate the antiviral action of drugs. Pulmonary surfactant (PS) assisted antiviral drug delivery by nanoemulsion system could be another effective approach for the treatment of COVID 19. Use of functional excipients like pulmonary surfactant (PS) and surfactant proteins (SPs), in the formulation of the antiviral drug-loaded nanoemulsion system can improve the treatment of coronavirus infection. Conclusion: In our opinion for synergizing antiviral action, lipid and protein portion of PS and their commercial analogs should be explored by pharmaceutical scientists to use them as a functional excipient in the formulation of antiviral drugloaded nanoemulsion system.

The Current Outbreak of COVID-19 with reference to India

Coronaviruses ◽  
2020 ◽  
Vol 01 ◽  
Author(s):  
Harshita Gupta
Keyword(s):  
Medical Research ◽  
Preventive Measures ◽  
Antiviral Drug ◽  
Treatment Strategies ◽  
Highly Pathogenic ◽  
Indian Council ◽  
Current Outbreak ◽  
Novel Coronavirus ◽  
Bat Coronavirus ◽  
Viral Outbreak

Abstract:: This review summarizes the outbreak of viruses causing the fatal disease which is highly pathogenic and human to human transmittable and it first emerges in Wuhan, China and now this epidemic situation becomes worldwide. A novel coronavirus (2019-nCoV) or severe acute respiratory syndrome coronavirus(SARS-CoV)-2 belongs to β-coronavirus genera which were originated in bats due to highly identical genome with bat coronavirus. This review highlights the Indian Council of Medical Research, India study which determined the detection of pathogenic coronavirus in two species of Indian bats. Indian Council of Medical Research, India has successfully isolated the COVID-19 virus strain which was the first step towards diagnosis and the development of vaccines in the country. The outbreaks of coronavirus received worldwide attention for overcoming the challenges faced during this current pandemic as there is no clinically approved antiviral drug or vaccine available, however, preventive measures and different treatments were taken to cope with this viral outbreak. In response to this global outbreak, this review tries to explain the Virology, Epidemiology, pathogenesis, and discusses the Diagnosis, treatment strategies of COVID-19. This review emphasizes the current update of knowledge about COVID-19.

scholarly journals An evidence-based systematic review on emerging therapeutic and preventive strategies to treat novel coronavirus (SARS-CoV-2) during an outbreak scenario

2020 ◽  
Vol 0 (0) ◽  
Author(s):  
Anupama M. Gudadappanavar ◽  
Jyoti Benni
Keyword(s):  
Antiviral Drug ◽  
Drug Repurposing ◽  
Respiratory Illness ◽  
World Health ◽  
Recombinant Vaccines ◽  
Subunit Vaccines ◽  
Coronavirus Infection ◽  
Novel Coronavirus ◽  
Health Organization ◽  
Full Length Genome

AbstractA novel coronavirus infection coronavirus disease 2019 (COVID-19) emerged from Wuhan, Hubei Province of China, in December 2019 caused by SARS-CoV-2 is believed to be originated from bats in the local wet markets. Later, animal to human and human-to-human transmission of the virus began and resulting in widespread respiratory illness worldwide to around more than 180 countries. The World Health Organization declared this disease as a pandemic in March 2020. There is no clinically approved antiviral drug or vaccine available to be used against COVID-19. Nevertheless, few broad-spectrum antiviral drugs have been studied against COVID-19 in clinical trials with clinical recovery. In the current review, we summarize the morphology and pathogenesis of COVID-19 infection. A strong rational groundwork was made keeping the focus on current development of therapeutic agents and vaccines for SARS-CoV-2. Among the proposed therapeutic regimen, hydroxychloroquine, chloroquine, remdisevir, azithromycin, toclizumab and cromostat mesylate have shown promising results, and limited benefit was seen with lopinavir–ritonavir treatment in hospitalized adult patients with severe COVID-19. Early development of SARS-CoV-2 vaccine started based on the full-length genome analysis of severe acute respiratory syndrome coronavirus. Several subunit vaccines, peptides, nucleic acids, plant-derived, recombinant vaccines are under pipeline. This article concludes and highlights ongoing advances in drug repurposing, therapeutics and vaccines to counter COVID-19, which collectively could enable efforts to halt the pandemic virus infection.

scholarly journals Insight of COVID-19/ SARS-CoV-2 and its Probable Treatment - A Mathematical Approach

2020 ◽  
Author(s):  
Amar Nath Chatterjee ◽  
Shubhankar Saha ◽  
Priti Kumar Roy ◽  
Fahad Al Basir ◽  
Evgenii Khailov ◽  
...  
Keyword(s):  
Drug Therapy ◽  
Side Effects ◽  
Complex Dynamics ◽  
Medical Science ◽  
Threshold Value ◽  
Drug Dosage ◽  
Equilibrium Analysis ◽  
Combination Drug ◽  
Drug Dosing ◽  
Novel Coronavirus

Abstract The novel coronavirus disease (COVID19) emerged in Wuhan, China in December 2019. In a matter of weeks, the disease had spread well outside China, and now reaching countries in all parts of the globe. Its treatment and recovery are the two most primary concerns for every country. Recently, medical science has shown some studies that reveal post-infection Hydroxychloroquine (HCQ) treatment followed by lipopeptide EK1C4 could be an effective interference in prevention of the disease COVID19, spreaded by SARS-CoV-2. However, there are some side effects of these drugs, especially for aged persons, but this is yet to be explored by rescaling the drug dosage with a proper dosing time interval.We propose a mathematical model that explains combination drug therapy on the dynamics of SARSCoV-2/COVID19. We apply the method of impulsive differential equation in our model and it is useful for elucidating insights into regular drug dosing. Systematic approach of this combination of drug therapy allows us to gain more fruitful results.In this model, we first investigate the chaotic nature of the system induced by SARS-CoV-2 with and without any treatment. Then we enquire how drug therapy reduces the threshold value of infection and observe its complex dynamics. We perform equilibrium analysis, local and global stability analysis and find the region of safe dosing so that there occurs no side-effects during treatment and afterwards. Our results suggest that only proper treatment enhances the stability in a SARS-CoV-2 infected system.

scholarly journals Use of Statins, Anticoagulants, Antiaggregants and Antiarrhythmic Drugs in Patients With COVID-19. The Agreed Experts’ Position of Russian Society of Cardiology, Eurasian Association of Therapists, National Society on Atherothrombosis, Societies of Experts in Urgent Cardiology, Eurasian Arrhythmology Association

Kardiologiia ◽  
2020 ◽  
Vol 60 (6) ◽  
pp. 4-14 ◽  
Author(s):  
Ye. V. Shlyakhto ◽  
G. P. Arutyunov ◽  
Yu. N. Belenkov ◽  
E. I. Tarlovskaya ◽  
A. O. Konradi ◽  
...  
Keyword(s):  
Drug Interaction ◽  
Antithrombotic Therapy ◽  
Antiarrhythmic Drugs ◽  
Antiviral Drug ◽  
Heart Rhythm ◽  
Antiviral Drugs ◽  
Russian Society ◽  
National Society ◽  
Heart Rhythm Disorders ◽  
Coronavirus Infection

This article discusses relevant aspects in the treatment of patients with COVID-19. Up-to-date information about principles for administration of statins, antithrombotics, and antiarrhythmics is presented. The authors addressed in detail specific features of reversing heart rhythm disorders in patients with coronavirus infection and the interaction of antiarrhythmic and antiviral drugs. Recommendations are provided for outpatient and inpatient antithrombotic therapy for patients with COVID-19. Issues of antithrombotic and antiviral drug interaction are discussed.

scholarly journals Diverse Effects of Exosomes on COVID-19: A Perspective of Progress From Transmission to Therapeutic Developments

2021 ◽  
Vol 12 ◽  
Author(s):  
Sangiliyandi Gurunathan ◽  
Min Hee Kang ◽  
Jin-Hoi Kim
Keyword(s):  
Vaccine Development ◽  
Antiviral Drug ◽  
Treatment Strategies ◽  
Antiviral Drugs ◽  
Therapeutic Benefits ◽  
Global Pandemic ◽  
Lung Injuries ◽  
Infected Cells ◽  
Intercellular Spread

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new strain of coronavirus and the causative agent of the current global pandemic of coronavirus disease 2019 (COVID-19). There are currently no FDA-approved antiviral drugs for COVID-19 and there is an urgent need to develop treatment strategies that can effectively suppress SARS-CoV-2 infection. Numerous approaches have been researched so far, with one of them being the emerging exosome-based therapies. Exosomes are nano-sized, lipid bilayer-enclosed structures, share structural similarities with viruses secreted from all types of cells, including those lining the respiratory tract. Importantly, the interplay between exosomes and viruses could be potentially exploited for antiviral drug and vaccine development. Exosomes are produced by virus-infected cells and play crucial roles in mediating communication between infected and uninfected cells. SARS-CoV-2 modulates the production and composition of exosomes, and can exploit exosome formation, secretion, and release pathways to promote infection, transmission, and intercellular spread. Exosomes have been exploited for therapeutic benefits in patients afflicted with various diseases including COVID-19. Furthermore, the administration of exosomes loaded with immunomodulatory cargo in combination with antiviral drugs represents a novel intervention for the treatment of diseases such as COVID-19. In particular, exosomes derived from mesenchymal stem cells (MSCs) are used as cell-free therapeutic agents. Mesenchymal stem cell derived exosomes reduces the cytokine storm and reverse the inhibition of host anti-viral defenses associated with COVID-19 and also enhances mitochondrial function repair lung injuries. We discuss the role of exosomes in relation to transmission, infection, diagnosis, treatment, therapeutics, drug delivery, and vaccines, and present some future perspectives regarding their use for combating COVID-19.

scholarly journals Associations of clinical characteristics and antiviral drugs with viral RNA clearance in patients with COVID-19 in Guangzhou, China: a retrospective cohort study

2020 ◽  
Author(s):  
Xudan Chen ◽  
Yuying Zhang ◽  
Baoyi Zhu ◽  
Jianwen Zeng ◽  
Wenxin Hong ◽  
...  
Keyword(s):  
Clinical Characteristics ◽  
Time Lag ◽  
Treatment Strategies ◽  
Antiviral Drugs ◽  
Viral Rna ◽  
The Novel ◽  
Illness Onset ◽  
Treatment Regimens ◽  
Global Pandemic ◽  
Novel Coronavirus

AbstractBackgroundThe novel coronavirus disease 2019 (COVID-19) characterized by respiratory symptoms has become a global pandemic although factors influencing viral RNA clearance remained unclear to inform optimal isolation period and treatment strategies.MethodsIn this retrospective study, we included patients with confirmed COVID-19 admitted to Guangzhou Eighth People’s Hospital from 20th January 2020 to 15th March 2020. The associations of clinical characteristics and treatment regimens on time to viral RNA clearance were analyzed.ResultsWe examined 284 consecutive COVID-19 cases, accounting for 82% of confirmed cases in Guangzhou during this period. At the time of reporting (20th March 2020), 276 (97.2%) had recovered and were discharged from hospital with a median hospital stay of 18 days (interquartile range [IQR]:13-24). Overall, 280 patients achieved viral RNA clearance with a median length of 12 days (IQR: 8-16) after onset of illness. Amongst them, 66.1% had viral RNA cleared within 14 days, and 89.3% within 21 days. Older age, severity of disease, time lag from illness onset to hospital admission, high body temperature, and corticosteroid use were associated with delayed clearance of viral RNA. None of the antiviral regimens (chloroquine, oseltamivir, arbidol, and lopinavir/ritonavir) improved viral RNA clearance. The use of lopinavir/ritonavir was associated with delayed clearance of viral RNA after adjusting for confounders.ConclusionIn patients with COVID-19, isolation for a minimum of 21 days after onset of illness may be warranted, while the use of antiviral drugs does not enhance viral RNA clearance.Brief SummaryViral RNA was cleared in 89% of the COVID-19 patients within 21 days after illness onset. The use of antiviral drugs (chloroquine, oseltamivir, arbidol, and lopinavir/ritonavir) did not shorten viral RNA clearance, especially in non-serious cases.

scholarly journals Rationale for a New Outpatient Drug Therapy Algorithm in COVID-19 Patients Based on the Principle of «Multi-hit» Approach

2021 ◽  
Vol 66 (3-4) ◽  
pp. 49-61
Author(s):  
K. A. Zykov ◽  
E. A. Sinitsyn ◽  
A. V. Rvacheva ◽  
A. O. Bogatyreva ◽  
A. A. Zykova ◽  
...  
Keyword(s):  
Drug Therapy ◽  
Practical Experience ◽  
Mechanisms Of Action ◽  
Multiple Exposure ◽  
Therapy Algorithm ◽  
Medical Institutions ◽  
Coronavirus Infection ◽  
Novel Coronavirus ◽  
Complex Algorithm ◽  
Outpatient Drug

The aim of the work was to justify the algorithm of outpatient drug therapy in patients with COVID-19, based on the principle of «Multi-hit» Approach. The algorithm is based on the published results of clinical studies and observations, authors’ own practical experience in the use and management of more than 4 thousand patients diagnosed with COVID-19 of varying severity during the 2020 pandemic. The article substantiates a complex algorithm for the treatment of outpatients with COVID-19, which includes etiotropic, pathogenetic, and symptomatic components of therapy with different mechanisms of action. The described approach is the 1st stage (outpatient) of a complex algorithm for managing patients with COVID-19. It has been successfully implemented in the system of outpatient care for patients with novel coronavirus infections in several leading medical institutions in Russia. The authors believe that the developed algorithm for providing outpatient drug therapy for COVID-19, based on the principle of multiple exposure, may be useful in real clinical practice of managing patients with coronavirus infection.

scholarly journals Update on recommendations for the diagnosis and treatment of SARS-CoV-2 infection in children

2020 ◽  
Vol 39 (12) ◽  
pp. 2211-2223 ◽  
Author(s):  
Hongjun Miao ◽  
Han Li ◽  
Yinying Yao ◽  
Mingfu Wu ◽  
Chao Lu ◽  
...  
Keyword(s):  
Treatment Strategies ◽  
Diagnosis And Treatment ◽  
The Novel ◽  
Treatment Standards ◽  
Wuhan City ◽  
Health Committee ◽  
Coronavirus Infection ◽  
Novel Coronavirus ◽  
The Impact ◽  
Pneumonia Diagnosis

AbstractSince the outbreak of novel coronavirus infection pneumonia in Wuhan City, China, in late 2019, such cases have been gradually reported in other parts of China and abroad. Children have become susceptible to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) because of their immature immune function. As the outbreak has progressed, more cases of novel coronavirus infection/pneumonia in children have been reported. Compared with adults, the impact of SARS-CoV-2 infection in children is less severe, with a lower incidence and susceptibility in children, which results in fewer children being tested, thereby underestimating the actual number of infections. Therefore, strengthening the diagnosis of the disease is particularly important for children, and early and clear diagnosis can determine treatment strategies and reduce the harm caused by the disease to children. According to the Novel Coronavirus Infection Pneumonia Diagnosis and Treatment Standards (trial version 7) issued by National Health Committee and the latest diagnosis and treatment strategies for novel coronavirus infection pneumonia in children, this review summarizes current strategies on diagnosis and treatment of SARS-CoV-2 infection in children.

Novel Pulmonary Delivery of Antiviral Drugs for Treating COVID-19 in Patients with Parkinson’s Disease

2021 ◽  
Vol 18 ◽  
Author(s):  
Nazrul Islam ◽  
Shafiqur Rahman
Keyword(s):  
Public Health ◽  
Drug Delivery ◽  
Antiviral Drug ◽  
Pulmonary Delivery ◽  
Therapeutic Benefit ◽  
Antiviral Drugs ◽  
Effective Strategy ◽  
Delivery Methods ◽  
Significant Burden ◽  
Delivery Technology

: The COVID-19 pandemic has caused a significant burden on public health worldwide. Currently, there are limited medications for the treatment of COVID-19 in patients with Parkinson’s disorder (PD). Several antiviral drugs and other pharmacotherapies have shown promise and are used by various delivery methods. Among the antiviral drugs, amantadine alone was reported to provide therapeutic benefit against COVID-19 in patients with PD. Here we propose novel strategies for pulmonary drug delivery technology of antiviral drug amantadine. As such pulmonary delivery of this drug or combination with the additional antiviral drugs could be a more effective strategy for the treatment of COVID-19-related complications in patients with PD. Furthermore, the important benefits and limitations of this novel delivery technology will be discussed.

scholarly journals A miRNA-PEPTIDE FUSION AS A VACCINE CANDIDATEAGAINST THE NOVEL CORONAVIRUS (COVID-19)

2020 ◽  
Keyword(s):  
In Silico ◽  
Published Data ◽  
Inhibiting Activity ◽  
The Novel ◽  
Antiviral Action ◽  
Preventive Vaccine ◽  
Immune Factor ◽  
The World ◽  
Coronavirus Infection ◽  
Novel Coronavirus

A new coronavirus named COVID-19 was reported in Wuhan, China in December 2019. The COVID-19 epidemic is spreading rapidly all over the world, (Sun P. and col, 2020). Based on published data on COVID-19, we have designed a preventive vaccine in Silico aimed to protect against COVID-19 infection and transmission (Cascella M. and col, 2020). One aim of this is to better understand potential dormant repositories of outbreaks and potential spread of those repositories, together with potential geogenic terrain factors (Wang Z., 2019). Here, we present to the miRNA-peptide fusion more stable as antiviral (Waterhouse A. and col 2018). As RNA target we used primers from Kemp V. “miRNA repertoire and host immune factor regulation upon avian coronavirus infection in eggs”: primers Biolegio, Nijmegen, The Netherlands (Kemp V. and col, 2019). Our analysis identified a miRNA-peptide with theorical fusion value stability FS=64.28, to treat COVID-19, named LCR_2020_B008-1. Additionally, peptide LCR_2020_B008 can be used in solutions as disinfectant and antiviral, having a fast-hygienic utility to avoid contagion or the propagation of the Covid-19 disease. With respect to antiviral action, the candidate manifests LCR_2020_B008-1, in Silico, manifesting partial inhibiting activity on the VIH-1, and therefore readjustments on this chimera miRNA-peptide could reach a representative antiviral activity against the VIH-1.

Sign in / Sign up

Export Citation Format

Share Document